A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma

By Jeran K. Stratford, D. Bentrem, Judy M. Anderson, C. Fan, K. Volmar, James Stephen Marron, Elizabeth D. Routh, L. Caskey, J. Samuel, C. Der and 8 more. 2010

224 citations recorded by the source corpus.

Jen Jen Yeh and colleagues developed and validated a six-gene signature in patients with pancreatic ductal adenocarcinoma that may be used to better stage the disease in these patients and assist in treatment decisions.

Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Yun Bai
2. Tianwei Yu
3. Zhaohui S. Qin
4. Rendong Yang
5. Matthew Stephens
6. Sharon R. Browning
7. Danyu Lin

Citations in the corpus

• EgoNet: identification of human disease ego-network modules (2014, background): “In the past decade, extensive work has been done to identify differentially expressed genes across different phenotypes, which can be used as diagnostic markers for classifying different disease states or predicting clinical outcomes [4-7].”
• CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T Cell Checkpoint Immunotherapy in Pancreatic Cancer Models (2014, unknown): “To determine the impact of these alterations, we applied these gene lists to existing gene expression datasets from patients with PDAC (22) and found that the core elements of the downregulated gene list were indicative of poor clinical outcomes (Fig.”